Agenda: Day 1

All session times are in Eastern Time (ET)

There are no agenda items with this track

8:00 am

8:00 am

Registration & Breakfast

  • Start your day off right and make connections with market access leaders
  • Interact with your peers, discuss best practices and share innovative strategies
  • Gather essential content and get exclusive offers at exhibit booths

9:00 am

9:00 am

Welcome From The Chair

Gain insight into today’s sessions so you can get the most out of your experience and maximize your value.

9:10 am

9:10 am

OPENING KEYNOTE: CANADIAN HEALTHCARE LANDSCAPE

CANADA’S HEALTHCARE SYSTEM – NOT AS BAD AS WE THINK (BUT NOT QUITE AS GOOD EITHER)

Not taking a page out of the COVID-19 playbook, the federal government and Canada’s 13 premiers are back to squabbling over healthcare funding. Meanwhile Canadians feel under-served for their tax dollars, and are fed up with temporary closures of ER’s and consistent staffing issues in all facets of healthcare. Exchange ideas and perspectives with one of Canada’s most respected – and always controversial – healthcare critics on topics including:

  • where does the future of healthcare funding lie
  • what can we as an industry do to increase Canadians’ access to new drugs
  • how can we make the healthcare sector more attractive for GenZ

Share your point of view and bring back actionable ideas to your senior management

10:00 am

10:00 am

FIRESIDE CHAT: THE INCREASED OPPORTUNITY FOR PUBLIC / PRIVATE PARTNERSHIPS TO FIX THE SYSTEM

Using Cardiovascular Disease As An Important Example

The healthcare system in Canada has been under tremendous strain for years. The ongoing crisis has been amplified by the pandemic, which caused severe global disruption in the delivery of health care for non-communicable diseases, BUT early detection and diagnosis are critical to keeping people out of hospitals and reducing the need for procedures and surgeries.

Now is the time to take a closer look at how the public and private sectors can band together to drive solutions to crucial healthcare problems, alleviate pressure throughout the system, and drive positive and lasting change.

The issue of cardiovascular disease (CVD) is particularly pressing as it is the second leading cause of death in Canada after cancer and now providers are facing an unprecedented backlog in the need for follow-up care to prevent future heart attacks and strokes among people at elevated risk. Novartis is seeking to address care inequities, barriers to access, and challenges and opportunities, by investing and institutionalizing best-in-class provincial teams to drive partnerships at the local healthcare system level.

10:30 am

10:30 am

Morning Break

  • Engage with conference speakers and fellow attendees
  • Secure new business contacts and discuss crucial developments in market access
  • Exchange innovations and ideas

11:00 am

11:00 am

QUÉBEC UPDATE

A New Life Sciences Strategy Moving Forward

Québec is outlining a revised Life Sciences strategy for the 2022-25 time period. Take advantage of the opportunity to interact with the chief architect of that thinking, covering topics including:

  • From a priority perspective, where do drugs for rare diseases fit in?
  • How will this new strategic direction affect the approval process for new drugs?
  • How will Medicare benefits and the current formulary be affected?

12:00 pm

12:00 pm

Networking Lunch

  • Expand your network and make connections that last beyond the event
  • Visit the exhibitor hall and pose your toughest questions to leading consultants
  • Enjoy great food and service while engaging with your pharma colleagues

1:00 pm

1:00 pm

PANEL DISCUSSION

IS RWE TRULY THE PANCEA WE ALL THINK IT IS/WILL BE?

RWE (real world evidence) has been hailed by many as the ‘magic bullet’ the industry – and Canadians overall – have been looking for it to speed up access to market for new medicines. But is it? Bring back learnings from other jurisdictions such as the UK to optimize your upcoming PLAs.

2:00 pm

2:00 pm

AFTERNOON KEYNOTE: ATTRACTING TALENT TO CANADA’S HEALTH & LIFE SCIENCES INDUSTRY

Combating the Health & Life Science “Brain Drain”

Of the 20 leading and emerging fintech hubs globally, Toronto ranked #8, Vancouver #12, Montreal #14 and Calgary #16. Unpack why the same can’t be said for Canada’s health and life sciences sector, and outline what can be done to change that. Take back strategies to galvanize your senior management (and MP) to build a resilient industry by:

  • Using the economic drivers of biotech and fintech as prime examples of successful strategy execution
  • Leveraging learning from key players
  • Incorporating government departmental mandates to strengthen the case for the benefit of all

 

2:30 pm

2:30 pm

INDUSTRY EXPERT

HOW CAN WE IMPROVE CANADA’S RELATIVE ATTRACTIVENESS FOR NEW PRODUCT LAUNCHES?

Canada ranks 10th out of 14 countries on its attractiveness for new medicine launch according to PDCI’s 2022 Biopharmaceutical Ecosystem Index. To ensure Canadian patients gain access to the new medicines of the future, we must keep pace with how constantly evolving local and international market access landscapes will affect Canada’s relative attractiveness for launch in the years to come. Develop your advocacy plan by:

  • Learning how Canada currently stacks up on its Development & Commercialization Infrastructure, Regulatory Landscape, and Market Access Environment
  • Identifying the policy areas that could most effectively improve our relative attractiveness
  • Discussing what Canada’s attractiveness rankings mean to Canadian patients

Share perspectives with your senior management that can help make a difference in future new drug launches

3:00 pm

3:00 pm

PANEL DISCUSSION: Drugs for Rare Diseases

Critical Elements for a National Strategy and Framework

With Health Canada preparing for the development and implementation of a national strategy for high-cost drugs for rare diseases, what can we learn from the COVID-19 vaccine journey? Leverage the experience of these market leaders to inform your market access strategy. Establish your game plan by:

  • Determining the types of partnerships and funding that will be key to the successful development of drugs for rare diseases
  • Analyzing the impact of recently increased government funding on the overall treatment pipeline
  • Visualizing potential safe and expeditious routes to commercialization for these medicines

Chart a course to succeed in the new market access model for rare disease therapies

4:00 pm

4:00 pm

PANEL DISCUSSION: THE ROAD TO ADVANCED THERAPEUTICS

Is Cell Gene Therapy ‘IT’?

Although still considered by some an experimental technique, cell gene therapy (CGT), which focuses on the genetic modification of cells, is poised to become much more prevalent. Researchers are constantly unveiling new approaches to gene therapy. Inform your development pipeline with an in-depth understanding of these strategies, including:

  • Replacing a mutated disease-causing gene with a healthy copy of the gene
  • Inactivating, or “knocking out,” a mutated gene that is functioning improperly
  • Introducing a new gene into the body to help fight a disease

Equip your team with actionable insights in your development of efficacious gene therapy products

4:30 pm

4:30 pm

Day One: Summary and Closing Comments from your Host

Review the key solutions and takeaways from today’s sessions. Source a summary of action points to implement in your work. Discuss tomorrow’s highlights!

4:45 pm

4:45 pm

Evening Reception

Don’t miss this chance to connect with speakers, attendees and sponsors! Unwind, mingle and build relationships that will benefit you in the years to come.

6:00 pm

6:00 pm

Conference Day 1 Adjourns

Get the latest news

*Privacy Policy